ArticleExperimental and clinical cardiology2004
Assessment of right ventricular fibrosis in different forms of pulmonary atresia with ventricular septal defect.
Article in Experimental and clinical cardiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn pulmonary atresia with ventricular septal defect (PA-VSD), the corrective surgical strategy aims to reduce the right ventricular (RV) overload and restore physiological pulmonary perfusion before the characteristic RV hypertrophy and fibrosis become irreversible.
objectiveTo assess RV fibrosis in different forms of PA-VSD.
methodsRV biopsies were obtained at corrective surgery from PA-VSD patients (n=14, mean age 2.5+/-1.2 years) with patent arterial duct (PAD group, n=6; mean age 1.7+/-0.5 years) or systemic-pulmonary collateral arteries (SPCA group, n=8; mean age 3.2+/-1.2 years) and from age-matched controls (control group, n=6; mean age 2.5+/-1.8 years). Myocardial expression patterns (messenger RNA [mRNA] and protein levels) of the extracellular matrix proteins (eg, fibronectin and collagens [subtype I alpha and III) were quantitatively analyzed in relation to myocardial cell hypertrophy.
resultsComparing the age of PA-VSD patients at surgery, the SPCA group was older than the PAD group (P=0.01). Expression analysis by reverse transcriptase polymerase chain reaction showed significantly higher mRNA levels in patients with PA-VSD for collagen III (PA-VSD versus controls; 0.9+/-0.2 versus 0.6+/-0.1, P=0.03) than in controls, whereas collagen I alpha and fibronectin mRNA levels did not differ. No differences were found between the PAD and SPCA groups. The myocyte cross sectional surface area showed enhanced myocyte hypertrophy in patients with PA-VSD compared with the control group (P=0.015), with no significant difference between the PAD and SPCA groups. Video image analysis of immunohistochemical staining corrected for hypertrophy revealed unchanged interstitial collagens and fibronectin levels in all groups. However, perivascular staining corrected for the vessel lumen area showed significantly lower total collagen levels in patients with PA-VSD than in the control group (3.2+/-1.2 versus 7.2+/-2.8, respectively; P=0.004).
conclusionsThe results indicate that the extracellular matrix support for the coronary blood vessels appears to be suboptimal in patients with PA-VSD. The staged surgical approach in the SPCA group (with a higher age at correction) did not result in an excessive accumulation of fibrosis markers in the RV myocardium.
Indexed as
Identifiers
19641724PMC2716745W135779366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.